Pfizer reports positive Phase 3 results for Braftovi

Pfizer (NYSE:PFE) reported positive topline results from a Phase 3 study of its drug Braftovi, also known as encorafenib, in the treatment of a certain type of colorectal cancer.

The study, called BREAKWATER, evaluated Braftovi in combination with Erbitux and mFOLFOX6 in